Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction when metformin alone is insufficient. - Type 2 diabetes mellitus (combined with other oral agents): offers further glucose control as part of multi‑drug regimens.

Common Side Effects: - Nasopharyngitis: mild upper respiratory infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat, or congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe allergic reactions: angioedema, anaphylaxis, or rash. - Hepatic injury: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome: serious skin blistering. - Severe hypoglycaemia: when combined with insulin or sulfonylureas. - Acute renal failure: rare but reported in susceptible patients.

Linagliptin should be used with clinical monitoring and awareness of patient‑specific factors. - Renal function assessment: evaluate eGFR before initiating therapy. - Hepatic function monitoring: check liver enzymes periodically. - Cardiovascular disease: use caution in patients with unstable heart conditions. - Combination with sulfonylureas or insulin: monitor for hypoglycaemia. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Concomitant use with insulin: increased risk of severe hypoglycaemia. - Duplicate DPP‑4 inhibition (other DPP‑4 inhibitors): may cause excessive pharmacologic effect. - Strong P‑gp inhibitors (e.g., itraconazole): may raise linagliptin plasma levels. Moderate Interactions (Monitor Closely): - Metformin: monitor renal function and lactic acidosis risk. - Rifampin: may reduce linagliptin exposure, consider dose adjustment. - Diuretics: watch for electrolyte disturbances. - ACE inhibitors: monitor blood pressure and renal parameters. - NSAIDs: assess for potential renal impairment.